Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
The drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss
TR
By Tom Reyes · Markets Editor
Nov 4 11:13 ETSource: BioPharma Dive
From the source
Read at biopharmadive.comNovo gets much-needed lift as Wegovy pill tops Wall Street forecasts
The drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines.
